Center-specific factors associated with peritonitis risk—a multi-center registry analysis

Peritoneal Dialysis International

Volumn 36, Issue 5, 2016, Pages 509-518

  Nadeau Fredette, Annie Claire ^a,b,c   Johnson, David W ^a,b,d   Hawley, Carmel M ^a,b,d   Pascoe, Elaine M ^a   Cho, Yeoungjee ^a,b,d   Clayton, Philip A ^b,e,f   Borlace, Monique ^g   Badve, Sunil V ^a,b   Sud, Kamal ^f,h   Boudville, Neil ⁱ   McDonald, Stephen P ^b,g,j  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Australia and New Zealand Dialysis and Transplant Registry   (Australia)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d TRANSLATIONAL RESEARCH INSTITUTE   (Australia)

^e PRINCE OF WALES HOSPITAL   (Australia)

^f University of Sydney   (Australia)

^g ROYAL ADELAIDE HOSPITAL   (Australia)

^h Westmead and Nepean Hospitals   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j UNIVERSITY OF ADELAIDE   (Australia)

more..

Author keywords

ANZDATA; Center; Mixed effects; Peritoneal dialysis; Peritonitis; Predictors

Indexed keywords

ANTIFUNGAL AGENT; ICODEXTRIN;

ADULT; AGED; ARTICLE; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PERITONITIS; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SENSITIVITY ANALYSIS; SURVIVAL RATE; AUSTRALIA; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; HEMODIALYSIS; INCIDENCE; MIDDLE AGED; MORTALITY; NEW ZEALAND; ORGANIZATION AND MANAGEMENT; PREDICTIVE VALUE; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REGISTER; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; RISK ASSESSMENT; TIME FACTOR;

AGED; AUSTRALIA; FEMALE; HEMODIALYSIS UNITS, HOSPITAL; HUMANS; INCIDENCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NEW ZEALAND; OUTCOME ASSESSMENT (HEALTH CARE); PERITONEAL DIALYSIS; PERITONITIS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TIME FACTORS;

EID: 84988649753     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2015.00146     Document Type: Article

References (39)

1. Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl 2006:S55–62.
2. Boudville N, Kemp A, Clayton P, Lim W, Badve SV, Hawley CM, et al. Recent peritonitis associates with mortality among patients treated with peritoneal dialysis. J Am Soc Nephrol 2012; 23:1398–405.
3. Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, Brown FG, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010; 77:904–12.
4. Ghali JR, Bannister KM, Brown FG, Rosman JB, Wiggins KJ, Johnson DW, et al. Microbiology and outcomes of peritonitis in Australian peritoneal dialysis patients. Perit Dial Int 2011; 31:651–62.
5. Nessim SJ, Bargman JM, Austin PC, Nisenbaum R, Jassal SV. Predictors of peritonitis in patients on peritoneal dialysis: results of a large, prospective Canadian database. Clin J Am Soc Nephrol 2009; 4:1195–200.
6. McDonald SP, Collins JF, Rumpsfeld M, Johnson DW. Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. Perit Dial Int 2004; 24:340–6.
7. Kerschbaum J, Konig P, Rudnicki M. Risk factors associated with peritoneal-dialysis-related peritonitis. Int J Nephrol 2012; 2012:483250.
8. Lim WH, Boudville N, McDonald SP, Gorham G, Johnson DW, Jose M. Remote indigenous peritoneal dialysis patients have higher risk of peritonitis, technique failure, all-cause and peritonitis-related mortality. Nephrol Dial Transplant 2011; 26:3366–72.
9. Cho Y, Johnson DW. Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis 2014; 64:278–89.
10. Cho Y, Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville N, et al. Effects of climatic region on peritonitis risk, microbiology, treatment, and outcomes: a multicenter registry study. Perit Dial Int 2013; 33:75–85.
11. Cho Y, Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville N, et al. The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. BMC Nephrol 2012; 13:41.
12. Chow KM, Szeto CC, Leung CB, Kwan BC, Law MC, Li PK. A risk analysis of continuous ambulatory peritoneal dialysis-related peritonitis. Perit Dial Int 2005; 25:374–9.
13. Cho Y, Badve SV, Hawley CM, McDonald SP, Brown FG, Boudville N, et al. Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. Nephrol Dial Transplant 2012; 27:2028–36.
14. Davenport A. Peritonitis remains the major clinical complication of peritoneal dialysis: the London, UK, peritonitis audit 2002–2003. Perit Dial Int 2009; 29:297–302.
15. Kavanagh D, Prescott GJ, Mactier RA. Peritoneal dialysis-associated peritonitis in Scotland (1999–2002). Nephrol Dial Transplant 2004; 19:2584–91.
16. Kopriva-Altfahrt G, Konig P, Mundle M, Prischl F, Roob JM, Wiesholzer M, et al. Exit-site care in Austrian peritoneal dialysis centers – a nationwide survey. Perit Dial Int 2009; 29:330–9.
17. Figueiredo AE, Moraes TP, Bernardini J, Poli-de-Figueiredo CE, Barretti P, Olandoski M, et al. Impact of patient training patterns on peritonitis rates in a large national cohort study. Nephrol Dial Transplant 2015; 30:137–42.
18. McDonald SP. Australia and New Zealand dialysis and transplant registry. Kidney Int Suppl (2011) 2015; 5:39–44.
19. Elder G, Faull R, Branley P, Hawley C. Caring for Australasians with Renal I. The CARI guidelines. Management of bone disease, calcium, phosphate and parathyroid hormone. Nephrology (Carlton) 2006; 11(Suppl 1):S230–61.
20. McMahon LP, MacGinley R, Kha C. KHA-CARI guideline: biochemical and haematological targets: haemoglobin concentrations in patients using erythropoietin-stimulating agents. Nephrology (Carlton) 2012; 17:17–9.
21. Skrondal A, Rabe-Hesketh S. Prediction in multilevel generalized linear models. J Royal Statistical Soc 2009; 172:659–87.
22. Chow J, Fortnum D, Moodie JA, Simmonds R, Tomlins M. The home network: an Australian national initiative for home therapies. J Ren Care 2013; 39(Suppl 1):56–61.
23. Huisman RM, Nieuwenhuizen MG, Th de Charro F. Patient-related and centre-related factors influencing technique survival of peritoneal dialysis in The Netherlands. Nephrol Dial Transplant 2002; 17:1655–60.
24. Ellis EN, Blaszak C, Wright S, Van Lierop A. Effectiveness of home visits to pediatric peritoneal dialysis patients. Perit Dial Int 2012; 32:419–23.
25. Martino F, Adibelli Z, Mason G, Nayak A, Ariyanon W, Rettore E, et al. Home visit program improves technique survival in peritoneal dialysis. Blood Purif 2014; 37:286–90.
26. Johnson DW, Clayton P, Cho Y, Badve SV, Hawley CM, McDonald S, et al. Weekend compared with weekday presentations of peritoneal dialysis-associated peritonitis. Perit Dial Int 2012; 32:516–24.
27. Johnson D, Brown F, Lammi H, Walker R. Caring for Australians with Renal I. The CARI guidelines. Dialysis adequacy (PD) guidelines. Nephrology (Carlton) 2005; 10(Suppl 4):S81–107.
28. Lan PG, Johnson DW, McDonald SP, Boudville N, Borlace M, Badve SV, et al. The association between peritoneal dialysis modality and peritonitis. Clin J Am Soc Nephrol 2014; 9:1091–7.
29. Bro S, Bjorner JB, Tofte-Jensen P, Klem S, Almtoft B, Danielsen H, et al. A prospective, randomized multicenter study comparing APD and CAPD treatment. Perit Dial Int 1999; 19:526–33.
30. Sanchez AR, Madonia C, Rascon-Pacheco RA. Improved patient/ technique survival and peritonitis rates in patients treated with automated peritoneal dialysis when compared to continuous ambulatory peritoneal dialysis in a Mexican PD center. Kidney Int Suppl 2008:S76–80.
31. Huang JW, Hung KY, Yen CJ, Wu KD, Tsai TJ. Comparison of infectious complications in peritoneal dialysis patients using either a twin-bag system or automated peritoneal dialysis. Nephrol Dial Transplant 2001; 16:604–7.
32. Rabindranath KS, Adams J, Ali TZ, Daly C, Vale L, Macleod AM. Automated vs continuous ambulatory peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2007; 22:2991–8.
33. Oo TN, Roberts TL, Collins AJ. A comparison of peritonitis rates from the United States Renal Data System database: CAPD versus continuous cycling peritoneal dialysis patients. Am J Kidney Dis 2005; 45:372–80.
34. Golper TA, Brier ME, Bunke M, Schreiber MJ, Bartlett DK, Hamilton RW, et al. Risk factors for peritonitis in long-term peritoneal dialysis: the Network 9 peritonitis and catheter survival studies. Academic Subcommittee of the Steering Committee of the Network 9 Peritonitis and Catheter Survival Studies. Am J Kidney Dis 1996; 28:428–36.
35. Cho Y, Johnson DW, Badve S, Craig JC, Strippoli GF, Wiggins KJ. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2013; 28:1899–907.
36. Piraino B, Bernardini J, Brown E, Figueiredo A, Johnson DW, Lye WC, et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31:614–30.
37. Walker A, Bannister K, George C, Mudge D, Yehia M, Lonergan M, et al. KHA-CARI guideline: peritonitis treatment and prophylaxis. Nephrology (Carlton) 2014; 19:69–71.
38. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30:393–423.
39. Perl J, Davies S, Lambie M, Pisoni R, McCullough KP, Johnson D, et al. The Peritoneal Dialysis Outcomes and Practice Patterns Study (PDOPPS): unifying efforts to inform practice and improve global outcomes in peritoneal dialysis. Perit Dial Int 2016; 36(3):297–307.